Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00745316 · ClinicalTrials.gov registry record · Phase 2
Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency
A Phase 2 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00745316 is a Phase 2 study that was terminated before completion, run by Biogen. The registered enrollment target is 34 participants.
The verdict
NCT00745316, a Phase 2 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safety and tolerability of tonapofylline (BG9928) when given at different doses to patients with heart failure and renal insufficiency. This study will also explore: * Disease related quality-of-life * Exercise capacity * Renal function * Concomitant medications
Interventions
- DRUG Placebo
- DRUG Tonapofylline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00745316
The ClinicalTrials.gov registry entry for NCT00745316 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00745316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00745316 about?
NCT00745316 is a clinical study titled "Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency". The main purpose of this study is to determine the safety and tolerability of tonapofylline (BG9928) when given at different doses to patients with heart failure and renal insufficiency. This study will also explore: * Disease related quality-of-life * Exercise capacity * Renal function * Concomit...
What is the current status of trial NCT00745316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2009-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00745316?
The interventions under investigation include: Placebo (DRUG), Tonapofylline (DRUG).
Who is sponsoring clinical trial NCT00745316?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.